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Abstract
Background: Aggregation and misfolded a-synuclein is thought to be central in the pathogenesis of Parkinson’s disease
(PD). Heat-shock proteins (HSPs) that are involved in refolding and degradation processes could lower the aggregate load of
a-synuclein and thus be beneficial in a-synucleinopathies.
Methodology/Principal Findings: We co-overexpressed human A53T point-mutated a-synuclein and human HSP70 in mice,
both under the control of Thy1 regulatory sequences. Behavior read-outs showed no beneficial effect of HSP70 expression
in mice. In contrast, motor coordination, grip strength and weight were even worse in the a-synucleinopathy model in the
presence of HSP70 overexpression. Biochemical analyses revealed no differences in a-synuclein oligomers/aggregates,
truncations and phosphorylation levels and a-synuclein localization was unchanged in immunostainings.
Conclusion/Significance: Overexpressing HSP70 in a mouse model of a-synucleinopathy did not lower the toxic load of a-
synuclein species and had no beneficial effect on a-synuclein-related motor deficits.
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Introduction
Mutations in the a-synuclein gene and multiplications of the a-
synuclein locus have been linked to familiar forms of PD [1–6]. In
addition, Lewy bodies, the pathological hallmark of sporadic PD,
contain aggregates of a-synuclein and multiple additional
components like ubiquitin [7,8]. a-synuclein is natively unfolded
and can self-aggregate to form oligomers and fibrils which are
believed to be involved in the pathogenesis of PD. Up-to-date, it is
unclear how and to what extent aggregates of a-synuclein
influences neuronal dysfunction and subsequently leads to
neurodegeneration. However, it is widely accepted that decreasing
a-synuclein oligomers, fibrils and aggregates will positively affect
a-synuclein-induced toxicity [9].
Heat shock proteins (HSPs) belong to the family of chaperone
proteins and are important in refolding misfolded proteins, in
preventing protein aggregate formation and targeting proteins to
proteasomal degradation [10,11]. It has been shown that HSPs
can be protective in several neurodegenerative models [12–15]. In
particular, HSP70 inhibits a-synuclein fibril assembly [16,17],
protects against a-synuclein toxicity in vitro [17–19] and reduces a-
synuclein aggregates in vivo [18]. We tested this hypothesis using
the mouse model of a-synucleinopathy that overexpresses human
a-synuclein containing the A53T point-mutation [20] and co-
overexpress HSP70, both under the control of the Thy1 promoter.
We demonstrate here that HSP70 has no beneficial effect on
behavior and a-synuclein aggregation in vivo.
Results and Discussion
Several studies report beneficial effects of HSPs, especially that
of HSP70 on a-synuclein aggregation and toxicity in vitro
[16–19,21] and in vivo [12,18]. HSPs function as molecular
chaperones; they are engaged in folding and refolding processes,
protein transport and in protein degradation. We tested the
hypothesis that HSP70 reduces the toxic load of a-synuclein in vivo.
We generated mice expressing human HSP70 (HSPA1A) under
the control of Thy1 regulatory sequences (Figure 1A). Five
founders were obtained and HSP70 expression was analysed by
immunohistology whereas one line had stable and high HSP70
expression (Figure 1B and 1C, named Thy1-HSP70 hereafter).
The transgene expression was highest in cortical, hippocampal
and brainstem areas, whereas it was low in the olfactory bulb and
cerebellum and absent in striatum. Thus, the expression pattern
reflects that of the Thy1 promoter observed before in other
transgenic mice utilizing the same promoter [20]. The Thy1-
HSP70 line was crossbred with Thy1-9813 (named Thy1-
haSN(A53T) hereafter) described earlier [20]. Thy1-haSN(A53T)
mice display severe motor coordination deficits and develop
subsequently neuropathology in several brain areas and degener-
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transgenic mice Thy1-HSP70/Thy1-haSN(A53T) showed a high
proportion of neuronal co-localization of HSP70 and a-synuclein
in different brain areas (Figure 1D). Only a few neurons were
single-positive for HSP70 or a-synuclein. This good overlap of
expression pattern makes these double transgenic animals suitable
for analyzing a beneficial effect of HSP70 on a-synucleinopathy.
The overexpression of HSP70 throughout the brain did not alter
behavior in Thy1-HSP70 compared to wild-type littermates
(Figure 2). Weight and forelimb muscle strength did not differ as
well as motor coordination tested by two different tasks. Thus, these
two groups were pooled (named control) for statistical analyses.
Thy1-haSN(A53T) mice showed at four months of age severe
motor coordination deficits (Figure 3 and [20]) and in addition
showed extensive muscle weakness. Weight was normal. However,
double transgenic Thy1-HSP70/Thy1-haSN(A53T) mice (age: 4
months) were even more impaired in their motor behavior (see
Figure 3, rotating beam at 4 rpm), had a more pronounced
forelimb muscle weakness and a significant reduction of weight
compared to single-positive Thy1-haSN(A53T) mice (Figure 3).
Mice were killed between six and seven months of age. It is very
difficult to assess histopathology in Thy1-haSN(A53T) mice as the
age of onset to manifest neuropathology is very heterogeneous and
hence, the quantification substantially variable. Thus, we focused
on the protein biochemistry of a-synuclein to analyse a-synuclein
oligomers and aggregates from these animals.
Protein extracts from spinal cord, brainstem and anterior brain
(lacking cerebellum and brainstem) from single and double
transgenic mice were analysed in immunoblots for HSP70 and a-
synuclein. Homogenates without detergent were generated and
soluble (supernatant after 13k rpm centrifugation) and pellet
(resuspension of crude pellet in detergent-free buffer after
centrifugation and removal of supernatant) fractions were
collected. As a negative control a-synuclein knock-out mice were
used. In soluble fractions from spinal cord and brainstem, Thy1-
haSN(A53T) showed a high overexpression of a-synuclein and
beside the a-synuclein monomer multiple bands for a-synuclein
were visible indicating the existence of a-synuclein oligomers/
aggregates (Figure 4A and 4C). Interestingly, a-synuclein
oligomers/aggregates could not be detected in pellet fractions
from brainstem (Figure 4C), spinal cord (data not shown) and in
soluble extracts from anterior brain (Figure 4D). Two truncated
forms of a-synuclein were detected in spinal cord and brainstem
that are absent in wild-type and a-synuclein knock-out (Figure 4A
and 4C) and somewhat weaker in pellet fractions of brainstem
(Figure 4C) and in anterior brain (Figure 4D). S129-phosphor-
ylated a-synuclein was, interestingly, very high in anterior brain
in soluble and pellet fractions (Figure 4D) and weak in spinal cord
and brainstem (Figure 4A and 4C). Higher molecular weight
species for a-synuclein (trimers, tetramers, etc.) could not be
observed as described elsewhere [9]. This could be because of a
different mouse line used or a different antibody recognizing
Figure 1. Mice overexpressing human HSP70 under the control of Thy1 regulatory sequences. A. Schematic diagram of the Thy1-HSP70
construct. B. Overview section of a Thy1-HSP70 mouse brain stained against HSP70. C. Details of brain sections from Thy1-HSP70 mice showing
HSP70 expression in different brain regions. Scale bars: 200 mm. D. Co-localization of human HSP70 (green) and human a-synuclein (red) in different
brain regions of double transgenic Thy1-HSP70/Thy1-haSN(A53T) mice. White arrow: Co-localization of HSP70 and a-synuclein; Red arrow: neurons
expressing only human a-synuclein; Green arrow: neurons single positive for human HSP70. Scale bars: 50 mm.
doi:10.1371/journal.pone.0010014.g001
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are not phosphorylated at serine 129. HSP70 protein can be
detected in soluble and pellet fractions and seems not to be
influenced by a-synuclein (Figure 4). Qualitative (spinal cord
(Figure 4A); single (n=5–6) and double transgenic (n=11) on
different immunoblots) and quantitative analysis of a-synuclein
oligomers/aggregates, truncations and phosphorylation in soluble
and pellet fractions of brainstem and anterior brain (Figure 4E)
(n=5, each for single and double transgenic mice) revealed no
significant change on a-synuclein oligomer/aggregated species,
truncations and S129-phosphorylation in Thy1-HSP70/Thy1-
haSN(A53T) double transgenic animals despite a strong HSP70
expression (Figure 4B, 4C and 4D). Brainstem samples somehow
show a greater variation in phosphorylated a-synuclein and in the
analysis of the pellet fraction compared to those from anterior
brain, although b-actin and HSP70 levels are relatively constant.
Only for a-synuclein monomers in the pellet fraction of anterior
brain could a small but significant reduction of 13% be observed.
This finding should be taken cautiously as our experience point to
a pure variability of the mouse line and/or of the pellet fraction
analyses. As no other parameter is significantly changed and,
more importantly, a-synuclein oligomers/aggregates are not
affected by the presence of HSP70 our conclusion is that
HSP70 has no effect on a-synuclein load. Our data does not
support the hypothesis that enhanced chaperone protein function
by HSP70 can alter a-synuclein misfolding in vivo. Although, a
possible explanation for a lack of chaperone effect on a-synuclein
metabolism could be due to a non-functional or only partially
functional HSP70 as in vivo functionality of the overexpressed
human HSP70 in mice has not been determined due to several
experimental challenges. Nevertheless, Thy1-HSP70/Thy1-haS-
N(A53T) double transgenic animals were even worse in motor
behavior than their single transgenic Thy1-haSN(A53T) litter-
mates. Several studies, however, claim that solely by the presence
of the chaperone HSP70 a-synuclein oligomer formation could
be prevented [16–19]. In contrast, others showed only positive
effects on a-synuclein fibers with HSP104 and not with HSP70
[22].
a-synuclein is normally synapticaly localized, however, neurons
with high overexpression of a-synuclein reveal a strong cytoplamic
and nuclear staining of mislocalized a-synuclein as seen in Thy1-
haSN(A53T) mice (see red arrows in Figure 1D). To evaluate if
excessive HSP70 expression could rescue this a-synuclein
mislocalization despite unchanged protein levels/oligomers we
looked in detail to the distribution of a-synuclein in Thy1-HSP70/
Thy1-haSN(A53T) mouse brains. There was no difference
detectable between Thy1-haSN(A53T) single-positive and Thy1-
HSP70/Thy1-haSN(A53T) double transgenic animals. Somatic/
nuclear a-synuclein localization was unchanged in different brain
areas (Figure 1D and 5).
Figure 2. Thy1-HSP70 mice appear and behave normally and are phenotypical indifferent to wildtype mice. Measurement of weight,
forelimb grip strength and motor coordination (rotating beam and rotarod) of single Thy1-HSP70 and wildtype mice. Error bars: SEM.
doi:10.1371/journal.pone.0010014.g002
Figure 3. HSP70 overexpression in an a-synucleinopathy mouse model is not beneficial but even worsens the phenotype.
Measurement of weight, forelimb grip strength and motor coordination (rotating beam and rotarod) of single- and double-transgenic Thy1-HSP70/
Thy1-haSN(A53T) mice. Asteriks indicate statistical significance (*: p,0.05, **: p,0.01; student’s t-test, two-tailed). Error bars: SEM.
doi:10.1371/journal.pone.0010014.g003
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Thy1-haSN(A53T) mice did not induce the expression of HSP70,
and Thy1-HSP70 mice did not show any change in endogenous a-
synclein levels (Figure 4). One would suggest that a-synuclein
overexpression is a stress factor to cells and as a consequence
would activate the heat-shock-response, amongst others HSP70.
However, we have not analysed the expression of other HSPs.
It has been reported that HSP27 but not HSP70 has a
protective effect on a-synuclein-induced toxicity [17,23] as well as
HSP104 in a rat model of Parkinson disease [22]. In addition,
HSP70 was not very effective in a polyglutamine mouse model
[24]. However, in toxin-induced mouse models HSP70 overex-
pression was protective [13]. Thus, other HSPs are needed besides
HSP70 to achieve clear positive effects on a-synucleinopathies.
In summary, our results demonstrate that HSP70 alone is not
sufficient to alter behavior deficits and a-synuclein species in a
mouse model of a-synucleinopathy.
Materials and Methods
Statement on Animal Welfare
All experiments were carried out in accordance with authori-
zation guidelines for the care and use of laboratory animals.
Studies described in this report were performed according to
Novartis animal license number 2063.
Transgenic Mice
Heat shock protein 70kDa 1A (HSPA1A) cDNA (1926 bp) was
cloned into the Thy1 cassette (van der Putten et al., 2000) and
transgenic Thy1-HSP70 mice were generated by pronuclear
injection (C57Bl/6 mouse eggs) of linearized (NotI) and purified
minigene. Transgenic mice were selected by PCR analysis of tail
DNA with primers Thy1for2 (59-GGGCTGACCTGGACAT-
TAGG-39) and HSP70rev2 (59-GTTCAGCGCCACCTGGTT
CT-39), which amplified with a standard PCR protocol a 991 bp
DNA fragment. Thy1-haSN(A53T) (van der Putten et al., 2000)
were genotyped by using primers HP45 (ACACCCCTAAAGCA-
TACAGTCAGACC) and HP42 (TGGGCACATTGGAACTGA
GCACTT), amplified DNA fragment: 1200 bp. Double transgen-
ic mice Thy1-HSP70/Thy1-haSN(A53T) were identified by PCR
analysis of tail DNA using two independent rounds of PCR, one
for Thy1-HSP70 and Thy1-haSN(A53T), respectively. Trangenic
mice were kept in C57Bl/6 background. For analyses males and
females were used.
Rotating Beam
The rotating beam was build in-house and is connected to a
rotarod apparatus (Lugo Basile, Italy). It consists of a metal beam
(Ø 1 cm, length 122 cm) coated with rubber attached to a rotarod
apparatus (gradient angle upwards of 10u) which controls the
constant rotating speed (4 rpm and 8 rpm). The beam is divided
Figure 5. Histological analyses reveal no difference in a-synuclein distribution/localization in the brain. Brain sections of single and
double transgenic Thy1-HSP70/Thy1-haSN(A53T) mice stained against human a-synuclein. Black arrow: cytoplasmic and nuclear a-synuclein in the
CA1 area of the hippocampus and brainstem neurons. Scale bar: 100 mm.
doi:10.1371/journal.pone.0010014.g005
Figure 4. Biochemical analyses of soluble and pellet fraction protein extracts from spinal cord, brainstem and anterior brain reveal
no difference in a-synuclein species. A. Immunoblot of mouse spinal cord lysates detecting soluble a-synuclein monomers, oligomers/
aggregates, truncations and S129-phosphorylation (P-aSN). B. Immunoblot of mouse spinal cord lysates detecting soluble HSP70. C. Immunoblot of
soluble (supernatant) and pellet fractions of brainstem detecting HSP70 and a-synuclein monomers, oligomers/aggregates, truncations and S129-
phosphorylation. D. Immunoblot of soluble (supernatant) and pellet fractions of anterior brain detecting HSP70 and a-synuclein monomers,
truncations and S129-phosphorylation (P-aSN). b-actin was used as loading control. The size markers are indicated. E. Bar graphs representing
quantitative analyses of the immunoblots shown in C and D for the a-synuclein monomers, oligomers/aggregates, truncated forms and S129-
phosphorylation (P-aSN) normalized to the loading control b-actin in soluble and pellet fractions. n=5 per genotype. Asteriks indicate statistical
significance (*: p,0.05); student’s t-test, two-tailed. Error bars: standard deviation.
doi:10.1371/journal.pone.0010014.g004
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performance of the mice (scores 1–5). The mouse is placed at
the beginning on the already rotating beam facing upwards. Score
1 (best): mouse reaches the end of the beam without falling down
or hanging on the beam head-down; Score 2: mouse falls down or
is hanging head-down in the section 4 of beam; Score 3: mouse
falls down or is hanging head-down in the section 3 of beam; Score
4: mouse falls down or is hanging head-down in the section 2 of
beam; Score 5: mouse falls down or is hanging head-down in the
section 1 of beam. Trials are finished, if a mouse reaches the end of
the beam, hangs at the beam head-down, or falls down completely.
One session consists out of two trials (each max. 1 min) of 4 rpm
and two trials of 8 rpm, whereas the sequence is one trial of 4 rpm
followed by on trial of 8 rpm in the morning and in the afternoon.
Rotarod
To measure motor coordination mice were placed on a
computerized treadmill (TSE rotarod system, Germany) and the
latency to fall-off the rotating rod is determined. The rotarod
program consists of three different running speeds (12 rpm,
24 rpm and 36 rpm) each for 30 sec with intervals of acceleration
lasting for 10 sec. Starting speed is 4 rpm. Rotarod performance
was assessed by evaluating the two best trials out of three
performed in one day.
Forelimb grip strength
To measure forelimb grip strength, mice are allowed to grasp a
handle connected to a force-measuring device (San Diego
Instruments, USA) and then pulled back with their tails until they
release the handle. The best out of four consecutive trials is
evaluated in N.
Biochemistry
All work was carried out at 4uC. Mouse brain was added to 5ml
homogenization buffer (20mM Tris-HCl, pH 7.4, 0.25M sucrose,
1mM EDTA, 1mM EGTA, 0.5mM PMSF, 0.5mg/ml pepstatin A
and leupeptin) without any detergent, then homogenized and
centrifuged in an Eppendorf centrifuge 5415R at 13000 rpm for
20 minutes at 4uC. The protein concentration of the supernatant
was determined using a protein assay kit (Bio-Rad Laboratories,
CA, USA). For immunoblot analysis, 10mg/slot of supernatant
(treated with NuPAGE LDS sample buffer (46) and NuPAGE
sample reducing agent (106)a t9 5 uC for 5 min) was analysed by
PAGE (NuPAGE Novex Bis-Tris gels (4–12%), Invitrogen, CA,
USA). The pellet fraction was dissolved in the same homogeni-
zation buffer as above without detergent (106volume of the tissue
weight) and then treated like and used according to supernatant
samples. For blotting XCell II blot module (Invitrogen, CA, USA)
was used. Detection was performed using the following antibodies:
Mouse monoclonal antibodies a-synuclein (1:500, BD Biosciences,
CA, USA), phosphorylated a-synuclein (1:5000, WAKO, Japan),
HSP70 (1:5000, StressGen, MI, USA) and as secondary antibody
the F(ab’)2 fragment of goat anti-mouse IgG, labeled with Alexa
Fluor 680 (1:2000, Invitrogen, CA, USA). The LI-COR Odyssey
System (LI-COR Biosciences GmbH, Germany) was used for
quantification of band intensities as described by the supplier.
Fluorescence intensities quantification was performed by stan-
dardization to b-actin levels using a mouse monoclonal anti b-
actin clone AC-15 antibody (1:5000, Sigma Aldrich, Switzerland).
Immunohistochemistry
PBS-perfused brains were postfixed overnight in 4% formalin
in PBS at 4uC. For paraffin sections, the brains were dehydrated
by different ethanol treatments using a Tissue-Tek VIP system
(GMI Inc, MI, USA). The ethanol treatment series consisted of
70%, 80%, 90%, 2694%, 36100% ethanol each for 1h. Brains
were then washed 2 times in xylol for 30 min followed by 2 times
in paraffin (30 min, 60 min). Subsequent, the dehydrated brains
were embedded at 55uC in paraffin using a Tissue Block System
TBS 88 (Geneq Inc, Canada). Slices were cut on a Microm HM
355 device (Microm International GmbH, Germany) at a
thickness of 4–5 mm and mounted on superfrost glass slides
(Microm International GmbH, Germany) and air-dried. Slides
were kept at room temperature until use. Paraffin was removed
by treating the slides with xylene (2610 min) followed by an
ethanol treatment series of 26100%, 2695% and 1670% (2–
3 min each). Slides were then rinsed 5 min in distilled water. For
immunohistochemistry of free-floating slices 50 mm thick vibra-
tome sections were cut of the post-fixed brains. Slides were
incubated 3610 min in day-1 buffer (0.01 M PBS, 1% BSA,
0.3% Triton X-100) and blocked by addition of 4% normal goat
serum for 20 min. Paraffin-embedded slides were incubated in
day-1 buffer with 1% normal goat serum and subsequently
incubated overnight with a mouse monoclonal anti-HSP70 (SPA-
810, 1:200, StressGen, MI, USA) and aSN antibody (1:800,
4B12, Abcam, UK) in a humidity chamber at room temperature.
Free-floating sections were incubated with HSP70 antibody (SPA-
810, 1:800, StressGen, MI, USA) and a-synuclein mouse
monoclonal antibody (Syn-1, 1:500; S63320, Transduction
Laboratories, Lexington, KY). Slides or sections were then rinsed
3610 min in day-2 buffer (day-1 buffer diluted 1:3 in 0.01M
PBS). Slides or sections were incubated for 1 h with secondary
antibody (Biotin-conjugated goat anti-mouse IgG (1:200, Vector-
labs, CA, USA) and then with ABC reagent (Vectorlabs, CA,
USA) for 1 h at room temperature. Slides or sections were then
rinsed in day-2 buffer 2610 min, in 0.01 M PBS 2620 min and
were then desalted in 0.01M Tris (pH 7.8). Free-floating brain
sections were mounted on glass slides. Slides were air-dried at
room temperature and coversliped with eukitt mounting medium
and analysed on a Nikon microscope.
Maintenance
The animals were housed in a temperature-controlled room
that was maintained on a 12 hr light/dark cycle. Food and water
were available ad libitum.
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